Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F.Clin Pharmacol Ther. 2020 May;107(5):1189-1199. doi: 10.1002/cpt.1712. Epub 2019 Dec 11.PMID: 31677154
Publicaties uit 2020
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment
Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, LöwenbergM, de Boer NK, Oldenburg B, Srivastava N, Jansen JM, Bodelier AGL, West RL, de Vries AC, Haans JJL, de Jong D, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC).Aliment Pharmacol Ther. 2020 Jul;52(1):123-134. doi: 10.1111/apt.15745. Epub 2020 May 22.PMID: 32441396
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC).Aliment Pharmacol Ther. 2020 May;51(9):880-888. doi: 10.1111/apt.15689. Epub 2020 Apr 1.PMID: 32237087